skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: Base de dados/Biblioteca: Wiley-Blackwell Full Collection 2013 remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Randomized controlled trial of irinotecan drug‐eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver‐limited metastasis
Randomized controlled trial of irinotecan drug‐eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver‐limited metastasis
Material Type:
Artigo 		Adicionar ao Meu Espaço

Randomized controlled trial of irinotecan drug‐eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver‐limited metastasis

Martin, Robert C. G. ; Scoggins, Charles R. ; Schreeder, Marshall ; Rilling, William S. ; Laing, Christopher J. ; Tatum, Clifton M. ; Kelly, Lawrence R. ; Garcia‐Monaco, Ricardo D. ; Sharma, Vivek R. ; Crocenzi, Todd S. ; Strasberg, Steven M.

Cancer, 2015-10, Vol.121 (20), p.3649-3658 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
2
Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C‐SCANS study
Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C‐SCANS study
Material Type:
Artigo 		Adicionar ao Meu Espaço

Muscle mass at the time of diagnosis of nonmetastatic colon cancer and early discontinuation of chemotherapy, delays, and dose reductions on adjuvant FOLFOX: The C‐SCANS study

Cespedes Feliciano, Elizabeth M. ; Lee, Valerie S. ; Prado, Carla M. ; Meyerhardt, Jeffrey A. ; Alexeeff, Stacey ; Kroenke, Candyce H. ; Xiao, Jingjie ; Castillo, Adrienne L. ; Caan, Bette J.

Cancer, 2017-12, Vol.123 (24), p.4868-4877 [Periódico revisado por pares]

United States: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por
3
FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors
Material Type:
Artigo 		Adicionar ao Meu Espaço

FOLFOX‐bevacizumab chemotherapy in patients with metastatic neuroendocrine tumors

Lacombe, Caroline ; Perrier, Marine ; Hentic, Olivia ; Brixi, Hedia ; De Rycke, Ophélie ; Cros, Jérôme ; Rebours, Vinciane ; Cadiot, Guillaume ; Ruszniewski, Philippe ; Mestier, Louis

Journal of neuroendocrinology, 2023-01, Vol.35 (1), p.e13227-n/a [Periódico revisado por pares]

United States: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por
4
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan
Material Type:
Artigo 		Adicionar ao Meu Espaço

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

Falvella, Felicia Stefania ; Cheli, Stefania ; Martinetti, Antonia ; Mazzali, Cristina ; Iacovelli, Roberto ; Maggi, Claudia ; Gariboldi, Manuela ; Pierotti, Marco Alessandro ; Di Bartolomeo, Maria ; Sottotetti, Elisa ; Mennitto, Roberta ; Bossi, Ilaria ; Braud, Filippo ; Clementi, Emilio ; Pietrantonio, Filippo

British journal of clinical pharmacology, 2015-09, Vol.80 (3), p.581-588 [Periódico revisado por pares]

England: John Wiley & Sons, Ltd

Texto completo disponível

Citações Citado por
5
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G
Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G
Material Type:
Artigo 		Adicionar ao Meu Espaço

Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild‐type KRAS colorectal cancer‐WJOG 6210G

Shitara, Kohei ; Yonesaka, Kimio ; Denda, Tadamichi ; Yamazaki, Kentaro ; Moriwaki, Toshikazu ; Tsuda, Masahiro ; Takano, Toshimi ; Okuda, Hiroyuki ; Nishina, Tomohiro ; Sakai, Kazuko ; Nishio, Kazuto ; Tokunaga, Shoji ; Yamanaka, Takeharu ; Boku, Narikazu ; Hyodo, Ichinosuke ; Muro, Kei

Cancer science, 2016-12, Vol.107 (12), p.1843-1850 [Periódico revisado por pares]

England: John Wiley & Sons, Inc

Texto completo disponível

Citações Citado por
6
Long‐term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C‐07 and LTS‐01
Long‐term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C‐07 and LTS‐01
Material Type:
Artigo 		Adicionar ao Meu Espaço

Long‐term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: Results from National Surgical Adjuvant Breast and Bowel Project trials C‐07 and LTS‐01

Kidwell, Kelley M. ; Yothers, Greg ; Ganz, Patricia A. ; Land, Stephanie R. ; Ko, Clifford Y. ; Cecchini, Reena S. ; Kopec, Jacek A. ; Wolmark, Norman

Cancer, 2012-11, Vol.118 (22), p.5614-5622 [Periódico revisado por pares]

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Texto completo disponível

Citações Citado por
7
First‐line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors
First‐line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors
Material Type:
Artigo 		Adicionar ao Meu Espaço

First‐line treatment with FOLFOXIRI for advanced pancreatic cancer in clinical practice: Patients' outcome and analysis of prognostic factors

Vivaldi, Caterina ; Caparello, Chiara ; Musettini, Gianna ; Pasquini, Giulia ; Catanese, Silvia ; Fornaro, Lorenzo ; Lencioni, Monica ; Falcone, Alfredo ; Vasile, Enrico

International journal of cancer, 2016-08, Vol.139 (4), p.938-945 [Periódico revisado por pares]

United States: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por
8
Improving the safety of high‐dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin
Improving the safety of high‐dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin
Material Type:
Artigo 		Adicionar ao Meu Espaço

Improving the safety of high‐dose methotrexate for children with hematologic cancers in settings without access to MTX levels using extended hydration and additional leucovorin

Vaishnavi, Kalthi ; Bansal, Deepak ; Trehan, Amita ; Jain, Richa ; Attri, Savita Verma

Pediatric blood & cancer, 2018-12, Vol.65 (12), p.e27241-n/a [Periódico revisado por pares]

United States: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por
9
Effect of neoadjuvant chemotherapy on postoperative morbidity and mortality in patients with locally advanced gastric cancer
Effect of neoadjuvant chemotherapy on postoperative morbidity and mortality in patients with locally advanced gastric cancer
Material Type:
Artigo 		Adicionar ao Meu Espaço

Effect of neoadjuvant chemotherapy on postoperative morbidity and mortality in patients with locally advanced gastric cancer

Ahn, H. S. ; Jeong, S.-H. ; Son, Y. G. ; Lee, H.-J. ; Im, S.-A. ; Bang, Y.-J. ; Kim, H.-H. ; Yang, H.-K.

British journal of surgery, 2014-11, Vol.101 (12), p.1560-1565 [Periódico revisado por pares]

Chichester, UK: John Wiley & Sons, Ltd

Texto completo disponível

Citações Citado por
10
Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5‐fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204
Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5‐fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204
Material Type:
Artigo 		Adicionar ao Meu Espaço

Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5‐fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204

Landry, Jerome C. ; Feng, Yang ; Cohen, Steven J. ; Staley, Charles A. ; Whittington, Richard ; Sigurdson, Elin Ruth ; Nimeiri, Halla ; Verma, Udit ; Prabhu, Roshan S. ; Benson, Al Bowen

Cancer, 2013-04, Vol.119 (8), p.1521-1527 [Periódico revisado por pares]

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (276)
  2. Revistas revisadas por pares (270)

Data de Publicação 

De até
Refinar
  1. Antes de1981  (29)
  2. 1981Até1990  (47)
  3. 1991Até2000  (89)
  4. 2001Até2011  (62)
  5. Após 2011  (62)
  6. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.